Condition: Opioid Use Disorder · Opioid Withdrawal · Opioid Craving · Sponsor: University of Maryland, Baltimore
The investigators propose a rigorous, Phase II, three-group, placebo-controlled double-blind randomized controlled trial (RCT) to evaluate the efficacy of buspirone for both withdrawal and craving among individuals with opioid use disorder (OUD) undergoing a standardized stepwise taper. During this 10 to 12-day residential study, participants with OUD will be enrolled, stabilized on a short-acting opioid, undergo an opioid stepwise taper, and complete a post-taper observation period where participants will have the opportunity to initiate long-term buprenorphine or extended-release naltrexone.
This description comes directly from the study's public registry record.
Cecilia Bergeria, Ph.D. · 410-550-1979 · cberge21@jhmi.edu
Caitlyn Grubb, B.S. · 410-550-0490 · cgrubb7@jhmi.edu
Always discuss trial participation with your own doctor first.
| Kahlert Institute for Addictino Medicin | Baltimore, Maryland, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05511909